Detalhe da pesquisa
1.
The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design.
Am Heart J
; 201: 141-148, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29803986
2.
Improvement of Local Cell Delivery Using Helix Transendocardial Delivery Catheter in a Porcine Heart.
Int Heart J
; 58(3): 435-440, 2017 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28539564
3.
Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.
Circ Res
; 114(8): 1292-301, 2014 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-24449819
4.
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
JAMA
; 311(1): 62-73, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24247587
5.
Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.
Circ Res
; 108(7): 792-6, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21415390
6.
Comparison of allogeneic vs autologous bone marrowderived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
JAMA
; 308(22): 2369-79, 2012 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23117550
7.
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy.
Am Heart J
; 161(3): 487-93, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21392602
8.
Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort.
Int J Cardiol
; 326: 131-138, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33091520
9.
Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study).
Am Heart J
; 154(1): 79.e1-7, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17584556
10.
Exploring heart lymphatics in local drug delivery.
Lymphat Res Biol
; 1(1): 47-53; discussion 54, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-15624321
11.
Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study).
EuroIntervention
; 7(7): 805-12, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22082576